Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miya BM
- Development stage
- Phase 4
- Lead developer
- Osel
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Miya BM is a live biotherapeutic product (LBP) containing the butyric acid-producing bacterial strain *Clostridium butyricum* MIYAIRI 588 (CBM 588). Developed and marketed by Miyarisan Pharmaceutical, it is an orally administered tablet used to modulate the gut microbiota and treat gastrointestinal conditions such as diarrhea, constipation, and dysbiosis. The mechanism of action involves the production of butyric acid, a short-chain fatty acid that provides energy to colonocytes, maintains the intestinal barrier, and regulates immune responses. Beyond its established use in gastroenterology since its 1970 approval in Japan, Miya BM is being investigated for its ability to enhance the efficacy of cancer immunotherapies by optimizing the host microbiome.
- Brand names
- Miya BMミヤBM錠
- Other names
- Clostridium butyricum MIYAIRI 588Miyairi bacteria
02
Targets
FFAR4 (Free fatty acid receptor 4)FFAR3 (Free fatty acid receptor 3)FFAR2HDAC (HDAC family)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on Miya BM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Miya BM.